AB1462 EFFECTIVENESS OF THE STILL ACTIVITY SCORE IN ADULT-ONSET STILL’S DISEASE
Authors: E. Uslu Yurteri, M. E. Yayla, B. Atmaca Haktaniyan, N. Göveç Giynaş, D. Sahin Eroglu, A. İlbay, R. Yilmaz, A. Usta, Y. Mahmutoğlu, T. M. Turgay, G. Kinikli, A. Ates
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Adults Still's disease is a rare autoinflammatory disorder with an unknown etiology, characterized by fever, arthritis, and rash. There is no method to fully evaluate the disease's activity [1]. <h3>Objectives</h3> The Still Activity Score (SAS) is a newly defined, easy-to-use disease activity assessment score for Still disease [2]. We aimed to compare the efficacy of the Modified Pouchot Activity Score (mPouchot), Systemic Feature Score (SFS), and Still Activity Score (SAS) [2-4]. <h3>Methods</h3> The study included 45 patients diagnosed with Still between 2010 and 2022 who met the Yamaguchi criteria. The patients were assessed using the physician global assessment (PGA) by two different physicians. Still, activity levels were computed. According to the severity of the disease, patients with PGA&lt;6 were categorized as having low disease activity, and those with PGA&gt;6 as having high disease activity. <h3>Results</h3> The demographic, clinical, and laboratory data for the patients are detailed in Table 1. There was a significant difference between the two groups in terms of mPouchot and SFS disease activity scores (low and high disease activity) (Table 1). CRP level was correlated with the SAS, SFS, and mPouchot disease activity scores (respectively; p=0.43, p=0.008, and p=0.011). Ferritin level was correlated with mPouchot and SFS disease activity score (respectively; p&lt;0.001, p=0.007) (Figure 1). There was a correlation between each score(p&lt;0.001). <h3>Conclusion</h3> SAS, a new disease activity score, correlated with previous activity scores. CRP levels were correlated with SAS. There was a correlation between the three disease activity scores. <h3>References</h3> [1]Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021 Aug;51(4):858-874. doi: 10.1016/j.semarthrit.2021.06.004. Epub 2021 Jun 13. PMID: 34175791. [2]Kalyoncu U, Kasifoglu T, Omma A, Bes C, Cinar M, Emmungil H, Kucuksahin O, Akar S, Aksu K, Yildiz F, Kanitez NA, Erden A, Bilgin E, Dalkilic E, Ermurat S, Hayran M. Derivation, and validation of adult Still Activity Score (SAS). Joint Bone Spine. 2022 Nov 21;90(1):105499. doi: 10.1016/j.jbspin.2022.105499. Epub ahead of print. PMID: 36423781. [3]Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J Rheumatol. 2010 Nov;37(11):2369-76. doi: 10.3899/jrheum.100247. Epub 2010 Sep 1. PMID: 20810496. [4]Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S, Iagaru N, Stefan M, Dinarello CA. Safety, and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011 May;63(5):1452-8. doi: 10.1002/art.30238. PMID: 21538322. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.